BNP Paribas Investors Back New Term for CEO Jean-Laurent Bonnafe
Shareholders at the bank's annual general meeting in Paris on Tuesday also voted to raise the age limit for the CEO role to 68 years, from 65 currently. The change was needed to allow the 63-year-old to stay on in his role until 2028.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
27 minutes ago
- Fox News
Russia strikes US electronics plant in latest attack on Ukraine
Fox News reporter Stephanie Bennett reports on a new airstrike by Russia that impacted a U.S. electronics plant near the Hungary border on 'Special Report.'
Yahoo
41 minutes ago
- Yahoo
CFO turnover spikes after record CEO exits last year
This story was originally published on CFO Dive. To receive daily news and insights, subscribe to our free daily CFO Dive newsletter. Dive Brief: Global CFO turnover increased during the first half of the year to a seven-year high on an annual basis, according to an analysis by leadership advisory firm Russell Reynolds Associates. A total of 173 public company CFOs were appointed in the first two quarters of the year, compared with 169 during the same period in 2024, according to the research. The latest number far surpasses the year-over-year average of 160 since 2019. 'This rise in turnover is driven by increased retirement rates and record high CEO turnover in 2024,' Russell Reynolds said in a report. Dive Insight: Starbucks is among public companies that have named a new CFO this year following a CEO departure. The coffeehouse chain announced in March that it tapped Cathy Smith, then CFO of Nordstrom, to become its finance chief, replacing longtime veteran Rachel Ruggeri. Smith received a cash signing bonus of $5 million as part of her compensation package. The move was part of a flurry of executive leadership changes at Starbucks after Brian Niccol was installed as CEO in September with the goal of turning around declining sales. Other companies that have announced CFO transitions this year after a CEO change include Boeing and healthcare company UnitedHealth. 'To mitigate rising CFO turnover, organizations should leverage best-practices in CFO succession planning, including using a new CFO's arrival as a trigger to assess the finance function, focus on bridging skills gaps, and formalize development plans,' the Russell Reynolds report said. Fifty-six percent of outgoing CFOs retired or moved to board roles exclusively in the first half of 2025, a seven-year high, according to the research. Fifty-seven percent of global incoming finance chiefs were appointed internally, slightly higher than 54% in the year-earlier period, an indication that CFO succession plans are starting to come to fruition, the report said. The findings are in line with trends the leadership advisory firm previously noted in a March report where it flagged early CFO retirement as a key factor behind high turnover, CFO Dive previously reported. Recommended Reading UPenn, University of Texas produce most CFOs Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Sarepta pushes off debt payments in bid to regain financial footing
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Sarepta on Thursday said it's reached agreements that remove about $700 million from a pile of debt due in 2027. The private agreements with debt holders will allow Sarepta to exchange the 1.25% convertible senior notes due in 2027 for $602 million worth of 4.875% convertible senior notes due in 2030, up to 6.7 million shares of Sarepta stock and about $123 million in cash. Separately, the company entered into a private placement of about 1.4 million shares. The transaction 'significantly enhances our balance sheet flexibility and strengthens our financial position,' Sarepta CEO Doug Ingram said in a statement. Sarepta will still have $450 million in existing convertible notes due in 2027. Dive Insight: Sarepta's fortunes have dramatically changed over the course of the last year. In June 2024, the company was riding high on an expanded approval for its Elevidys gene therapy treatment for Duchenne muscular dystrophy. Its shares soared, topping $160 that month. But the trajectory for Elevidys sales changed when the company reported a patient death in March of this year and then another in June. The Food and Drug Administration in July asked Sarepta to stop shipping the therapy, a request that Sarepta initially refused. While the FDA allowed Elevidys shipments to resume for certain patients in the U.S. in late July, the sales outlook for the therapy is uncertain, and investors have punished Sarepta's stock. The shares were trading at less than $20 apiece early Thursday. The questions about Elevidys sales also raised new concerns about whether Sarepta could repay looming debt and make hundreds of millions of dollars in milestone payments to its partner, Arrowhead Pharmaceuticals. Even after laying off more than a third of its staff, analysts questioned whether Sarepta would need to make more cuts to meet its commitments. Sarepta is answering those questions with a series of financial transactions. In addition to the latest refinancing of 2027 debt, Sarepta last week announced that it planned to sell its entire equity stake in Arrowhead. After both moves, 'we are well positioned to fully fund our pipeline and meet our near-term obligations,' Sarepta CEO Ingram said in the company's statement Thursday. The transactions will help ease investors' immediate concerns about Sarepta's balance sheet, Leerink Partners analyst Joseph Schwartz wrote in a Thursday note to investors. 'With the near-term overhang removed, we think investor focus will remain squarely on how demand for Elevidys trends following the safety events and regulatory saga,' he wrote. Recommended Reading 4 more biotechs cut staff amid market tumult Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
